Dr. Richard Larson received his medical degree from the Stanford University School of Medicine, and completed his postdoctoral training in internal medicine, hematology, and oncology at the University of Chicago. He was a fellow of the Leukemia Society of America. Dr. Larson is Professor of Medicine in Hematology/Oncology at the University of Chicago and Director of the Hematologic Malignancies Clinical Research Program. He was the Director of the Leukemia Clinical Research Program from 1983 to 2000, during which time he established the medical center's allogeneic blood and marrow transplant program.

Dr. Larson is the past chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB) and is a member of the European LeukemiaNet committees for AML and CML. He has served as a Councillor and Officer of the American Society of Hematology, and represented ASH as a member of the National Cancer Policy Forum of the National Academy of Medicine. He has also served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine. Dr. Larson has served on the editorial boards of Blood, the Journal of Clinical Oncology, and Leukemia, and is an editor-in-chief for hematology for UpToDate. His research interests include clinical trials in hematologic malignancies and stem cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related myeloid neoplasms.